Livagen vs AICAR
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Livagen is a dipeptide bioregulator (Lys-Glu) developed by Professor Vladimir Khavinson, tissue-specific for the liver and thymus. It supports hepatocyte function, promotes liver cell regeneration, and modulates immune function via thymic activity. Research suggests benefits in chronic liver disease, hepatic aging, and immune restoration following liver damage.
- AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
- Half-Life
- Short (minutes); gene-regulatory effects are sustained
- ~2–3 hours
- Admin Route
- SubQ, Oral
- SubQ, IV
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 25–50 mg
- Frequency
- Daily for 10–30 days
- 3–5 times per week
- Key Benefits
- Supports hepatocyte regeneration and liver tissue repair
- Normalizes liver cell protein synthesis
- Immune modulation via thymic activity
- Potential benefits in chronic hepatitis and liver aging
- Anti-aging effects on hepatic tissue
- May support liver recovery after toxic insult or alcohol damage
- Complementary to NAD+ and glutathione in liver health protocols
- AMPK activation mimics aerobic exercise adaptations
- Increased fat oxidation and endurance
- Mitochondrial biogenesis (PGC-1alpha)
- Improved insulin sensitivity and glucose metabolism
- Anti-inflammatory effects
- Potential cardiac protection during ischemia
- Synergistic with actual exercise training
- Reduces hepatic glucose production
- Side Effects
- Generally well tolerated
- Mild injection site reactions
- No significant hepatotoxic effects reported at standard doses
- Hypoglycemia risk
- Lactic acidosis at high doses (animal data)
- Injection site irritation
- Stacks With
- —
- —